$100,000 to invest ( INVESTING 2020 ) | My First Million Podcast
About this video
Sam and Shaan evaluate three hypothetical business investments—Cron Art, Res Karat, and Lilia—and debate which deserves $100,000. They discuss the merits of marketplace models versus other business structures, then pivot to analyzing GoPuff, a fast-delivery service on college campuses that their guest mentions as an overlooked opportunity, examining its business model and profitability against comparable companies.
Key takeaways
- Shaan would invest in Res Karat because he believes fine art marketplaces are underserved by technology and the marketplace model is more defensible than lead-gen alternatives
- Sam prefers Cron because it can reach default profitability quickly with high impulse-buy demand, potentially reaching $10–30M in recurring revenue in 3–4 years with minimal capital, and faces acquisition interest from large productivity-focused companies
- The guest highlights GoPuff as a validated $163M-revenue model on college campuses that demonstrates the viability of fast-delivery logistics for impulse purchases, noting that even massive funding rounds (Softbank) don’t guarantee success in crowded markets
Episode details: published April 5, 2020 · 609 views · 5:16 long. Summary written by Self Growth Videos from the episode itself. The business ideas, figures and results discussed are the hosts’ and guests’ own claims, shared as brainstorming and entertainment — not verified facts and not investment advice.
← Previous: Buying Art | My First Million Podcast · Next: GaryVee & Sam Parr Talk About How The Hustle Started | My First Million Podcast →
All My First Million videos · My First Million profile · My First Million (official site)
You Might Also Enjoy

These 4 Math Equations Will Make You A Millionaire | Alex Hormozi
Explore →
3 businesses we think are about to blow up
Explore →
We tested Instinct, Muse and Grokbot. They’re ridiculous.
Explore →
People are doing $100M+ in sales on this app (ft. Whatnot founder)
Explore →
The $4 billion business behind drug testing
Explore →